Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A1 | P60842 | 19/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Silvestrol SCHEMBL29391620 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| Silvestrol SCHEMBL19678561 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| Silvestrol SCHEMBL19683897 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| Silvestrol SCHEMBL24180257 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| Silvestrol SCHEMBL19666161 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| Silvestrol SCHEMBL24426807 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| Silvestrol SCHEMBL29959484 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| Silvestrol SCHEMBL5807124 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| Silvestrol SCHEMBL19508495 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| Silvestrol SCHEMBL18862668 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025071306-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING LYMPHOMA COMPRISING BCL-2 INHIBITOR, SELECTIVE NUCLEAR EXPORT PROTEIN INHIBITOR, AND ELF4A INHIBITOR | 연세대학교 산학협력단 | 2025-04-03 | — | — | WO | claimed |
| EP-3305290-B1 | SILVESTROL AND EPISILVESTROL FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | PHILIPPS UNIV MARBURG (DE) | 2022-11-30 | — | — | EP | claimed |
| WO-2022035308-A1 | A COMPOSITION FOR THE TREATMENT OF AUTOIMMUNE DISEASES | THE GOVERNMENT OF THE STATE OF SARAWAK, MALAYSIA (MY) | 2022-02-17 | — | — | WO | claimed |
| US-20250345307-A1 | SYNTHETIC ROCAGLATES WITH BROAD-SPECTRUM ANTIVIRAL ACTIVITIES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-11-13 | — | — | US | disclosed |
| WO-2025071306-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING LYMPHOMA COMPRISING BCL-2 INHIBITOR, SELECTIVE NUCLEAR EXPORT PROTEIN INHIBITOR, AND ELF4A INHIBITOR | 연세대학교 산학협력단 | 2025-04-03 | — | — | WO | disclosed |
| WO-2025071306-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING LYMPHOMA COMPRISING BCL-2 INHIBITOR, SELECTIVE NUCLEAR EXPORT PROTEIN INHIBITOR, AND ELF4A INHIBITOR | 연세대학교 산학협력단 | 2025-04-03 | — | — | WO | disclosed |
| WO-2023196135-A1 | METHOD FOR PREPARING T CELLS FOR ADOPTIVE T CELL THERAPY | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230313140-A1 | METHOD FOR PREPARING T CELLS FOR ADOPTIVE T CELL THERAPY | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2023-10-05 | — | — | US | disclosed |
| CN-115996716-A | EIF4A inhibitor combinations | 效应治疗股份有限公司 | 2023-04-21 | — | — | CN | disclosed |
| US-11576933-B2 | Compositions and methods for an improved antitumor immune response | Effector Therapeutics Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| EP-4125884-A1 | EIF4A INHIBITOR COMBINATIONS | Effector Therapeutics Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20220378821-A1 | METHODS OF TREATING BRAF-MUTATED CANCER CELLS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2022-12-01 | — | — | US | disclosed |
| EP-3305290-B1 | SILVESTROL AND EPISILVESTROL FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | PHILIPPS UNIV MARBURG (DE) | 2022-11-30 | — | — | EP | disclosed |
| EP-3305290-B1 | SILVESTROL AND EPISILVESTROL FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | PHILIPPS UNIV MARBURG (DE) | 2022-11-30 | — | — | EP | disclosed |
| US-11427595-B2 | Compositions and methods for inhibiting viral infection | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220151976-A1 | TARGETING LASP1, EIF4A1, EIF4B AND CXC4 WITH MODULATORS AND COMBINATIONS THEREOF FOR CANCER THERAPY | THE UNIVERSITY OF TOLEDO (US) | 2022-05-19 | — | — | US | disclosed |
| EP-3993875-A1 | METHODS OF TREATING BRAF-MUTATED CANCER CELLS | EFFECTOR THERAPEUTICS, INC. (US) | 2022-05-11 | — | — | EP | disclosed |
| US-11279708-B2 | Amidino- and amino-rocaglates as novel translation inhibitors and anticancer agents | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-03-22 | — | — | US | disclosed |
| WO-2022035308-A1 | A COMPOSITION FOR THE TREATMENT OF AUTOIMMUNE DISEASES | THE GOVERNMENT OF THE STATE OF SARAWAK, MALAYSIA (MY) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151976-A1 | TARGETING LASP1, EIF4A1, EIF4B AND CXC4 WITH MODULATORS AND COMBINATIONS THEREOF FOR CANCER THERAPY | LASP1, CXCL12, LAS1L | EIF4A1 9/4885CYP3A4 4464/4885HIF1A 1832/4885 |
| US-20220378821-A1 | METHODS OF TREATING BRAF-MUTATED CANCER CELLS | BRAF, EIF4EBP1, EIF4E | EIF4A1 62/4885CYP3A4 4860/4885HIF1A 1957/4885 |
| US-11279708-B2 | Amidino- and amino-rocaglates as novel translation inhibitors and anticancer agents | EIF2B3, EIF4EBP1, G3BP1 | EIF4A1 22/4885CYP3A4 3701/4885HIF1A 3317/4885 |
| US-20250345307-A1 | SYNTHETIC ROCAGLATES WITH BROAD-SPECTRUM ANTIVIRAL ACTIVITIES AND USES THEREOF | SARS1, RNGTT, ACE2 | EIF4A1 180/4885CYP3A4 912/4885HIF1A 3860/4885 |
| US-11427595-B2 | Compositions and methods for inhibiting viral infection | HAVCR2, MAVS, EIF2AK2 | EIF4A1 837/4885CYP3A4 3559/4885HIF1A 957/4885 |
| US-11576933-B2 | Compositions and methods for an improved antitumor immune response | EIF4A2, EIF4A1, EIF4EBP1 | EIF4A1 2/4885CYP3A4 4788/4885HIF1A 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.